Patent intelligence · US
US 11419934
Use of VDAS to enhance immunomodulating therapies against tumors
Use of VDAS to enhance immunomodulating therapies against tumors
Patent details — US 11419934
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 23, 2022
- Expiration
- Aug 18, 2042
- Applicant
- Oncotelic Therapeutics, Inc.
- Claims
- 5
- CPC classes
- A61K, A61K2039/505, A61K31/661, A61K31/6615
Quick answer
US 11419934 (Use of VDAS to enhance immunomodulating therapies against tumors) is held by Oncotelic Therapeutics, Inc.. Status: granted. Granted Aug 23, 2022. Expires Aug 18, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Oncotelic Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K2039/505, A61K31/661, A61K31/6615, A61K39/395, A61K39/3955
Related coverage
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
FDA Approves Atezolizumab for ctDNA MRD-Positive MIBC: A New Era for Adjuvant Therapy
The U.S. Food and Drug Administration (FDA) has approved atezolizumab (Tecentriq) for the adjuvant treatment of adult patients with muscle-invasive bladder cancer (MIBC) who have ctDNA molecular residual disease (MRD) positivity after radical cystectomy. This approval signifies a major step forward in personalized adjuvant therapy for this patient population.
FDA Approves Atezolizumab for Muscle-Invasive Bladder Cancer
The FDA has approved Atezolizumab for muscle-invasive bladder cancer, marking a significant advancement in oncology treatment options. This approval has important implications for investors and pharmaceutical teams.
FDA Approves Tecentriq for Extensive-Stage Small Cell Lung Cancer
The FDA has granted approval for Tecentriq, a groundbreaking treatment for extensive-stage small cell lung cancer, enhancing options for patients in need.
Frequently asked questions
What is US patent 11419934?
US 11419934 (Use of VDAS to enhance immunomodulating therapies against tumors) is held by Oncotelic Therapeutics, Inc.. Status: granted. Granted Aug 23, 2022. Expires Aug 18, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11419934?
Oncotelic Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 11419934 expire?
Our index shows an expiration date of Aug 18, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.